Disappointingly, similar studies performed in patients with PD have drawn inconsistent conclusions in which results from a small RCT did not show any significant improvement in the tamoxifen group compared with the placebo group (Teloken et al., 1999)
Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicenter, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Presented for research literature review only Ito S et al
Atri, A
Squillacioti C, Pelagalli A, Liguori G, Mirabella N
Metabolites 12:1 Hafiz R, Gandhi TK, Mishra S, Prasad A, Mahajan V, Di X, Natelson BH, Biswal BB (2022) Higher limbic and basal ganglia volumes in surviving covid-negative patients and the relations to fatigue